Second chance: drug retrial for patients whose blood disorder came back
NCT ID NCT07039422
Summary
This study is for adults with two specific blood disorders (ITP and wAIHA) who previously benefited from the drug ianalumab but later saw their condition worsen. It aims to see if giving a second course of the same drug is safe and effective at controlling the disease again. The study will enroll about 60 people who participated in earlier trials of this medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGRoeselare, West-Vlaanderen, 8800, Belgium
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
RECRUITINGOstrava, Poruba, 708 52, Czechia
-
Novartis Investigative Site
RECRUITINGFlorence, FI, 50134, Italy
-
Novartis Investigative Site
RECRUITINGVicenza, VI, 36100, Italy
-
Novartis Investigative Site
RECRUITINGGeorge Town, 10050, Malaysia
-
Novartis Investigative Site
RECRUITINGSingapore, 119074, Singapore
-
Novartis Investigative Site
RECRUITINGSamsun, Atakum, 55200, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGLondon, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.